The FDA approves camizestrant for ER-positive, HER2-negative metastatic breast cancer with ESR1 mutations. Learn about this new treatment option and its clinica
tozorakimab COPD therapy shows significant reduction of inflammation by targeting multiple pathways, offering new hope beyond eosinophil‑focused treatments.
Eosinophil guided steroid reduction in COPD cuts ICS doses without raising severe flare‑ups, according to the COPERNICOS trial…
The FDA approves camizestrant for ER-positive, HER2-negative metastatic breast cancer with ESR1 mutations. Learn about this new treatment…
Adjunct antipsychotics are emerging as a promising option for treating depression when antidepressants fall short, offering new hope…
Cancer telehealth is bridging the vast distance barrier for Mountain West patients, offering remote specialist access and reducing…
Evolocumab reduces heart attack risk by 20% in high-risk patients with atherosclerosis or diabetes, lowering mortality rates effectively.
Myasthenia Gravis survival is better than Multiple Sclerosis in new data. Patients with MG live 15 to 19…
FDA approves rusfertide (Mimrylo) for erythrocytosis, sparing polycythemia vera patients from painful phlebotomies. Read the latest medical news.
The DOJ drops the Olmstead defense in Texas v. Kennedy, shifting from defending HHS rules to siding with…
New study reveals significant weight loss outcomes with up to 16.6% mean weight loss and reduced liver fat…
